Dezmopresin

Dezmopresin
(IUPAC) ime
	(2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-; (diaminomethylideneamino)-1-oxopentan-2-yl]-1-; [(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-; (3-amino-3-oxopropyl)-16-[(4-hydroxyphenyl)methyl]-; 6,9,12,15,18-pentaoxo-13-(phenylmethyl)1,2-dithia-; 5,8,11,14,17-pentazacycloicosane-4-carbonyl]; pyrrolidine-2-carboxamide
Klinički podaci
Identifikatori
CAS broj	16679-58-6
ATC kod	H01BA02
PubChem	5311065
DrugBank	BTD00112
ChemSpider	10481973
KEGG	D00291
ChEMBL	CHEMBL376685
Hemijski podaci
Formula	C46H64N14O12S2
Mol. masa	1069.22 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C46H64N14O12S2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52)/t28-,29-,30-,31-,32-,33-,34-/m0/s1 ; Key: NFLWUMRGJYTJIN-NXBWRCJVSA-N
Farmakokinetički podaci
Bioraspoloživost	Varijabilno; 0.08–0,16 % (oralno)
Vezivanje za proteine plazme	50%
Poluvreme eliminacije	1.5–2.5 časa
Izlučivanje	Renalno
Farmakoinformacioni podaci
Trudnoća	B2(AU) B(US)
Pravni status	POM (UK) ℞-only (SAD)
Način primene	IV, IM, supkutano, intranazalno, oralno

Dezmopresin (DDAVP, Stimat, Minirin) je sintetička zamena za vazopresin, hormon koji umanjuje proizvodnju urina. On se može koristiti nazalno, intravenozno, ili u obliku tablete. Dezmopresin se najčešće koristi za lečenje insipidnog dijabetesa ili enureze.^[6]

Hemija uredi

Dezmopresin (1-dezamino-8-D-arginin vazopresin) je modifikovana forma normalnog humanog hormona arginin vazopresina, peptida koji sadrži devet aminokiselina.

U poređenj sa vazopresinom, prva aminokiselina dezmopresina je deaminisana, i arginin u osmoj poziciji je u dekstro umesto levo formi.

Način dejstva uredi

Dezmopresin deluje putem ograničavanja količine vode koja se eliminiše urinom.

Dezmopresin vezuje V2 receptore u bubrezima, što dovodi do povećanja reapsorpcije vode. On takođe stimuliše oslobađanje von Vilebrandovog faktora iz endotelnih ćelija kao posledica stimulacije V1a receptora.

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11 izd.). New York: McGraw-Hill. ISBN 0-07-142280-3.

Literatura uredi

Leissinger C, Becton D, Cornell C Jr, Cox Gill J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001;7:258-66. PMID 11380629.

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

Šablon:Neuropeptidni ligandi

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[Goodman-6] Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). Goodman & Gilman's The Pharmacological Basis of Therapeutics (11 izd.). New York: McGraw-Hill. ISBN 0-07-142280-3.

[6]

[1]

[2]

[3]

[4]

[5]